世界の主要なジェネリック医薬品メーカー分析...市場調査レポートについてご紹介

1. Report Overview
1.1 Introduction to this Survey
1.2 Main Report Findings
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methods of Research and Analysis
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Top 50 Generic Drug Manufacturers
2.1 Top 50 Generic Drug Manufacturers: Revenues and Ranking, 2014
2.2 Top 50 Generic Drug Companies: Revenue Analysis, 2014
2.3 Top 50 Generic Drug Companies Regional Distribution, 2014
2.4 Report Coverage
2.5 Report Complexity
2.5.1 Obtaining Data from Private Companies
2.5.2 Financial Years Variability
2.5.3 Generics Revenue Identification
2.5.4 Defining Generics 1: Difference Between Biosimilars and Generics
2.5.5 Defining Generics 2: ‘Super-Generics’ and APIs
2.5.6 Defining Generics 3: Rx and OTC

3. Top North American Generic Drug Manufacturers: Activities and Prospects, 2015-2025
3.1 Companies Covered in this Chapter
3.2 Leading US Generic Drug Manufacturers: Financial Performance Outline, 2014
3.3 Mylan: Number One US Manufacturer of Generic Drugs: Company Overview, 2015
3.3.1 Mylan Historical Performance and Financial Results Analysis, 2015
3.3.2 Mylan Generic Drugs Revenue Forecast, 2015-2025
3.3.3 First Class II Transdermal Approval Consolidates Mylan’s Top Status in the US Market
3.3.4 Tender System Hurts Mylan’s German Market Share but the Company Retains its Australian Dominance
3.3.5 Mylan’s Focus on Complex Generics: Reasons and Causes
3.3.6 Mylan’s Generic Portfolio Remains the Company’s Core Strength
3.3.7 Mylan’s Winning Acquisition Strategy
3.3.8 Mylan Acquired Abbott: Towards Scale Economies and Vertical Integration
3.3.9 Mylan’s Potential Acquisition Plans – Outlook
3.4 Pfizer – The Leading Research-Based Pharmaceutical: Company Overview, 2015
3.4.1 Pfizer Historical Performance and Financial Results Analysis, 2015
3.4.2 Pfizer Generic Drugs Revenue Forecast, 2015-2025
3.4.3 Pfizer Internationalization and Restructuring Strategy
3.4.4 Pfizer’s Acquisition of Hospira: A Solution for Boosting the Generic Revenue Stream?
3.4.5 Prospects for Pfizer’s Generic Drugs Business
3.5 Abbott: Company Overview, 2015
3.5.1 Abbott Business Segments Performance
3.5.2 Abbott Historical Performance and Financial Results Analysis, 2015
3.5.3 Abbott Generic Drugs Revenue Forecast, 2015-2025
3.5.4 Abbott’s Acquisitions: Overview and Analysis, 2010-2014
3.5.5 Abbott’s Sale of its Overseas Branded Generic Business: Implications
3.5.6 Future Prospects for Abbott Generic Drugs Business
3.6 Hospira: Company Overview, 2015
3.6.1 Integrated Infusion Therapies and Other Hospira Businesses
3.6.2 Hospira – Injectable Expert Among the Top 10 Generic Companies Acquired by Pfizer
3.7 Apotex: Company Overview, 2015
3.7.1 Apotex Expansion to Europe and Beyond
3.7.2 Apotex Drives Business Diversification Through R&D
3.8 Par Pharmaceuticals: Company Overview, 2015
3.8.1 Par Pharmaceuticals’ Acquisition of JPH Group Holdings
3.8.2 Concentrated Generic Revenue Stream and Over 60 Generic Prescription Drugs
3.8.3 Buy Out of Indian Ethics Bio Lab Demonstrates Par’s Interest in Niche Products
3.9 Valeant Pharmaceuticals: Company Overview, 2015
3.9.1 Valeant: A Major Challenger in the Emerging Markets
3.9.2 Branded Generics are Crucial to Valeant’s Emerging Market Ambitions
3.9.3 Valeant Implements Acquisition Strategy to Boost Revenues
3.9.4 Valeant Generic Drugs Revenue Forecast, 2015-2025
3.10 Endo Pharmaceuticals: Company Overview, 2015
3.10.1 Endo: Pain Expertise in Branded and Generic Drugs
3.10.2 Endo’s Expansion on the South African Market
3.10.3 Performance Analysis on Endo’s Qualitest Business
3.10.4 Future Prospects for Endo Pharmaceuticals Generic Drugs Business
3.10.5 Endo Generic Drugs Revenue Forecast, 2015-2025
3.11 Pharmascience – Another Major Canadian Player: Company Overview, 2015
3.11.1 Over 200 Generic Product Families
3.11.2 Korean Venture Driving Diversification for Pharmascience
3.12 Mallinckrodt: Company Overview, 2015
3.12.1 Mallinckrodt Generics: Valuable Addition to the Company’s Portfolio
3.12.2 Reclassification of Methylphenidate ER Products: Effects on Mallinckrodt’s Income
3.12.3 What is Mallinckrodt’s Advantage Against Strong Competition?
3.12.4 Partnerships and Acquisitions: Crucial for Mallinckrodt’s Rapid Expansion
3.13 Akorn Pharmaceuticals: Company Overview, 2015
3.13.1 Akorn Acquisition of Small Companies: A Strategic Shift Towards Broad Market Reach
3.13.2 Akorn Strengthens its Position on the US Ophthalmology Market
3.14 Alvogen – A Privately-Owned US Company is the One to Watch: Company Overview, 2015
3.14.1 Alvogen Unique Business Model Proves Good Results
3.14.2 Alvogen Target is to Become Top 10 Global Generic Player
3.15 Sagent Pharmaceuticals – One of the Fastest Growing Providers of Specialty Generics in the US: Company Overview, 2015
3.15.1 Will Sagent’s Different Business Model Achieve Growth?

4. Top European Generic Drug Manufacturers: Activities and Prospects, 2015-2025
4.1 Companies Covered in this Chapter
4.2 Leading European Generic Drug Manufacturers: Financial Performance Outline, 2014
4.3 CEE Markets Home to Many Big Generic Contenders
4.4 Novartis (Sandoz) – the World’s Second Largest Generic Pharmaceutical Company: Overview, 2015
4.4.1 Novartis (Sandoz) Historical Performance and Financial Results Analysis, 2015
4.4.2 Novartis (Sandoz) Generic Drugs Revenue Forecast, 2015-2025
4.4.3 Novartis (Sandoz) Key Developments Analysis, 2015
4.4.4 Europe is the Main Market for Sandoz
4.4.5 Emphasis on Complex, Differentiated Generics and Biosimilars
4.4.6 Future Prospects for Novartis Generic Drugs Business
4.5 Actavis: Company Overview, 2015
4.5.1 Actavis Historical Performance and Financial Results Analysis, 2015
4.5.2 Actavis Generic Drugs Revenue Forecast, 2015-2025
4.5.3 Implications of Actavis Large Product Portfolio
4.5.4 Actavis Customized Commercial Model for International Markets
4.5.5 Merger Creates New Force in the Generic Drug Industry
4.5.6 Actavis Acquisition of Forest Laboratories: Move Towards Specialty Pharmaceuticals
4.5.7 The Acquisition of Auden McKenzie Will Add More than 150 Products to Actavis Product Line
4.5.8 Actavis Acquired Allergan with Aim to be a Top 10 Pharmaceutical Company
4.6 Sanofi: Company Overview, 2015
4.6.1 Sanofi Historical Performance and Financial Results Analysis, 2015
4.6.2 Sanofi Generic Drugs Revenue Forecast, 2015-2025
4.6.3 Adaptive Business Model for Sanofi’s Generic Drug Division
4.6.4 Zentiva Benefits from Strong Presence in the EU Market
4.6.5 Future Prospects for Sanofi Generics
4.7 Fresenius Kabi – Leading Generic Intravenous Drug Player: Company Overview, 2015
4.7.1 Intra Venous Drugs: The Main Product Line for Fresenius Kabi
4.7.2 Fresenius Kabi Will Continue to Expand
4.8 Pharmstandard – The Biggest Russian Pharmaceutical Manufacturer: Company Overview, 2015
4.8.1 Acquisitions Strengthen Pharmstandard Manufacturing and Product Base
4.8.2 Pharmstandard Benefits from Strong Organic Production Capacity
4.8.3 Future Prospects for Pharmstandard Generic Drugs Business
4.8.4 Pharmstandard Generic Drugs Revenue Forecast, 2015-2025
4.9 Gedeon Richter – Hungarian Leader Looking Further Afield: Company Overview, 2015
4.9.1 Female Health and Fertility Segments Form Core Strengths for Gedeon Richter
4.9.2 Specialisation Strategy for Further Growth
4.9.3 A Pan-European Pharmaceutical Presence for the Future?
4.9.4 Gedeon Richter Generic Drugs Revenue Forecast, 2015-2025
4.10 Krka – Slovenian Generic Giant Active in 70+ Countries: Company Overview, 2015
4.10.1 Prescription Generics: Krka’s Major Focus
4.10.2 Russia is the Largest National Market for Krka, but for How Long?
4.10.3 Krka Generic Drugs Revenue Forecast, 2015-2025
4.11 Stada Arzneimittel – Major Presence in Germany and Central Europe: Company Overview, 2015
4.11.1 Negative Effect from the CIS Region Crisis
4.11.2 Strong Product Development with Over 600 Product Launches in 2014
4.11.3 Stada Targets the Biosimilar Sector with Promising Deals
4.11.4 Stada Arzneimittel Generic Drugs Revenue Forecast, 2015-2025
4.12 Perrigo: Company Overview, 2015
4.12.1 Perrigo Drives Generic Segment Growth through Acquisitions, but Will it be Acquired Itself?
4.12.2 Rx Pharmaceuticals: Main Contributors to Perrigo’s Revenue Stream
4.13 Polpharma – Poland’s Generic Powerhouse: Company Overview, 2015
4.13.1 Polpharma’s Continuous Product Portfolio Enlargement
4.13.2 Strong Regional Presence in Poland, Russia and Kazakhstan
4.13.3 Acquisition Increases Polpharma Dominance in the Polish Market

5. Top Indian Generic Drug Manufacturers: Activities and Prospects, 2015-2025
5.1 Companies Covered in This Chapter
5.2 India: Generics Supplier to the World
5.3 Top 10 Indian Generic Drug Manufacturers: Financial Performance Outline, 2014
5.4 Sun Pharmaceutical – Leader in the Indian Generic Drug Market, Company Overview, 2015
5.4.1 Sun Has a Leading Presence in the Generic Export Market
5.4.2 Mega Acquisitions to Enlarge Sun’s Operations?
5.4.3 Sun Pharmaceutical Generic Drugs Revenue Forecast, 2015-2025
5.5 Dr. Reddy’s Laboratories: Company Overview, 2015
5.5.1 At the Forefront of the Indian Generic Boom: Dr. Reddy’s Revenue Exceeded $2bn in 2014
5.5.2 North America and Russia are the Largest Export Markets for Dr. Reddy’s
5.5.3 Alliance with GlaxoSmithKline
5.5.4 Dr. Reddy’s Early Leadership in Biosimilar Antibodies
5.5.5 Dr. Reddy’s: Generic Drugs Revenue Forecast, 2015-2025
5.6 Lupin – The Most Successful Indian Generic Firm in the US Market: Company Overview, 2015
5.6.1 Lupin’s Continuous Portfolio Growth and Focus on Complex Injectables
5.6.2 Strong R&D Investment in New Delivery Systems and Original Products
5.6.3 Lupin Generic Drugs Revenue Forecast, 2015-2025
5.7 Cipla – Mumbai Based Generic Giant: Company Overview, 2015
5.7.1 Generic Copaxone: A Major Product Launch for Cipla
5.7.2 Cipla’s Leadership in Anti-Retroviral Drugs and Focus on Key Markets
5.7.3 Chronic Disease: A Significant Target for Cipla
5.7.4 Cipla Generic Drugs Revenue Forecast, 2015-2025
5.8 Ranbaxy -The Second Largest Indian Generic Manufacturer with Sales in 150+ Countries: Company Overview, 2015
5.8.1 Dermatological Therapeutics: Targeted Area of Growth for Ranbaxy
5.8.2 ANDA Applications Giving Promising Opportunities
5.8.3 High Income Stream from the Emerging Markets
5.8.4 Merger with Sun
5.9 Aurobindo – The Largest FDA APIs Supplier, Moved Into Original Drugs: Company Overview, 2015
5.9.1 High-Margin Specialty Generics
5.9.2 ANDA Filings and Approvals by Region, 2014
5.9.3 CRAMS Opportunities
5.10 Glenmark – Specialty Company Still Leveraging Generic Growth: Overview, 2015
5.10.1 Generics Remain Part of Global Growth Strategy for Glenmark
5.10.2 Glenmark Benefits from Africa and Middle East Exports Boom
5.10.3 Glenmark Generic Drugs Revenue Forecast, 2015-2025
5.11 Wockhardt -Increasing Presence in US and Europe Generics Market: Company Overview, 2015
5.11.1 US Market Growth in 2014
5.11.2 Biosimilars, Novel Delivery Systems and Original Drugs will Drive Growth for Wockhardt
5.12 Cadila – Leader in Indian Cardiovascular Market: Company Overview, 2015
5.12.1 Biochem Acquisition Boosts Cadila’s Revenue
5.12.2 Increasing Presence in the US Market
5.12.3 Cadila: A Future Biosimilar Force?
5.13 Ipca Laboratories – One of Top 10 Indian Pharma Exporters: Company Overview, 2015
5.13.1 Fast Development Due to Niche Strategic Approach

6. Top Generic Drug Manufacturers from the Rest of the World: Activities and Prospects, 2015-2025
6.1 Companies Covered in this Chapter
6.2 Leading Rest of the World Generic Drug Manufacturers: Financial Performance Outline, 2014
6.3 Japanese and Brazilian Generic Environment Particularly Significant to the Global Generic Drug Market
6.4 Teva Pharmaceutical Industries: Company Overview of the World’s Generic Industry Leader, 2015
6.4.1 Teva Historical Performance and Financial Results Analysis, 2010-2014
6.4.2 Teva Generic Drugs Revenue Forecast, 2015-2025
6.4.3 Teva’s Global Presence
6.4.4 How did Teva Achieve its Success?
6.4.5 Teva Operational Strategy: Focus on Cost Reduction
6.4.6 The US Market Stagnates but Teva Sustains its Strong Penetration
6.4.7 From Volume to Value Driven Strategy in the European Markets
6.4.8 Teva Strengthens its Position in the Central Nervous System Market Through the Acquisition of Auspex Pharma
6.4.9 Will Mylan Eventually Join Teva’s Long Acquisition List?
6.4.10 Future Prospects for Teva Generic Drugs Business
6.5 EMS – Leading the South American Generic Market: Company Overview, 2015
6.5.1 First Brazilian Company to Export Generics to Europe
6.5.2 EMS Has the Most Advanced Latin American R&D Base
6.6 Aspen Pharmacare – South African Giant Continues to Expand: Company Overview, 2015
6.6.1 Ten-Year CAGR to 2014 Exceeds 25%
6.6.2 Philippines Added to Areas of Activity
6.6.3 Continuing Over 30% Dominance in South Africa Generic Market
6.6.4 Asia-Pacific and International Business Main Revenue Contributors in 2014
6.6.5 Europe/CIS and Latin America: Another Major Growth Opportunity for Aspen
6.6.6 Aspen Generic Drugs Revenue Forecast, 2015-2025
6.7 Nichi-Iko: Company Overview, 2015
6.7.1 More Than 900 Generic Products in Nichi-Iko Portfolio
6.7.2 Nichi-Iko Venture with Sanofi Complements Strategy
6.8 Abdi Ibrahim: Turkey’s Leading Pharmaceutical Company
6.8.1 Large Product Portfolio Helps to Sustain Market Position
6.8.2 Abdi Ibrahim has a Vast International Scope
6.9 Hypermarcas SA – Brazilian Pharmaceutical and OTC Giant: Company Overview, 2015
6.9.1 Price Increase and High Profit Margins: Would they be Sustainable?
6.10 Eurofarma – Rapidly-Growing Generics Power in Brazil: Company Overview, 2015
6.10.1 Eight Diversified Business Divisions
6.10.2 M&A Extending Latin American Reach for Eurofarma
6.11 Taro Pharmaceuticals – The Second Largest Israeli Pharmaceutical Manufacturer: Company Overview, 2015
6.11.1 FDA Corticosteroid Spray Approval Boosts Taro’s Portfolio in 2014
6.12 Towa Pharmaceuticals – Another Big Japanese Player: Company Overview, 2015
6.12.1 Large Number of Generic Products in Towa’s Portfolio
6.12.2 Towa’s Broad and Expanding Production Capacity
6.13 Sawai Pharmaceuticals – Osaka-Based Generic Leader: Company Overview, 2015
6.13.1 Annual manufacturing Capacity of 10bn Tablets
6.13.2 Cardiovascular Drugs are the Most Significant Therapeutic Area for Sawai
6.13.3 M&A Boosts Sawai’s R&D

7. Interviews from Our Survey
7.1 Interview with Jean-Marie Arnaud, Senior Vice President and Head of Sanofi Generics
7.1.1 Sanofi Generics Act with the Expertise of Sanofi Group
7.1.2 Sanofi Uses Innovative and Adapted Business Model Worldwide
7.1.3 Increasing Revenues for Sanofi Generics as the Company Continues to Focus on Emerging Markets and Portfolio Enlargement
7.1.4 A Generic Product is no Longer Just a Pure Copy of an Original
7.1.5 The Usage of Generic Medicines in Europe Can Still be Optimised
7.1.6 A Combination of Strategies Proves Successful in the Generics Industry
7.2 Interview with a Representative of the Generic Pharmaceutical Association (GPhA)
7.2.1 86% of all Prescriptions in the US are for Generic Drugs
7.2.2 Patent Settlements Provide Higher Savings and Early Market Entry for Generics
7.2.3 The Cost Burden will Increase if the Generic Drug Labelling Rule Changes
7.2.4 Biosimilars – the New Target for Generic Drug Manufacturers

8. Conclusions
8.1 Companies’ Growth Strategies
8.2 Why are Big Pharma Companies Targeting Generics?
8.3 Watson and Actavis Merger: The First Major Consolidation for the Generic Drug Industry
8.4 The Changing Dynamics of the Generic Drug Companies
8.5 Big Pharma Business Models Evolve
8.6 Biosimilars Will Have a Transformative Effect on Both Generic and Originator Drug Companies
8.7 Complex Generics with High Entry Barriers Continue to Increase in Importance
8.8 Future Trends for Generic Drug Producers – What’s Possible?